In an aging society, needs for transdermal medicine are growing since many aged patients have difficulties of swallowing oral medicaments. By using Kaneka’s expertise technology and Know-How in polymer materials, we pursue developing innovative and unique medical products that meet physicians' needs and contribute to the QOL of patients, while leveraging its strong network with leading pharmaceutical companies.
*KM Transderm Ltd., which became a wholly owned group company of Kaneka in September 2017, is in charge of developing products in this business area.
*Directed to an external website
We’re contributing to drugs in a broad range of fields by tapping our biotechnology and synthesis technology as core technologies, from conventional synthetic pharmaceuticals to leading-edge biotechnology-based drugs. We continue to supply valuable solutions to pharmaceutical manufacturers around the world.